An Immunological Review of SARS-CoV-2 Infection and Vaccine Serology: Innate and Adaptive Responses to mRNA, Adenovirus, Inactivated and Protein Subunit Vaccines
The coronavirus disease 2019 (COVID-19) pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, which is defined by its positive-sense single-stranded RNA (ssRNA) structure. It is in the order Nidovirales, suborder Coronaviridae, genus Betacoronavirus, and sub-g...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/11/1/51 |
| _version_ | 1797436630754131968 |
|---|---|
| author | Suhaila A. Al-Sheboul Brent Brown Yasemin Shboul Ingo Fricke Chinua Imarogbe Karem H. Alzoubi |
| author_facet | Suhaila A. Al-Sheboul Brent Brown Yasemin Shboul Ingo Fricke Chinua Imarogbe Karem H. Alzoubi |
| author_sort | Suhaila A. Al-Sheboul |
| collection | DOAJ |
| description | The coronavirus disease 2019 (COVID-19) pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, which is defined by its positive-sense single-stranded RNA (ssRNA) structure. It is in the order Nidovirales, suborder Coronaviridae, genus Betacoronavirus, and sub-genus Sarbecovirus (lineage B), together with two bat-derived strains with a 96% genomic homology with other bat coronaviruses (BatCoVand RaTG13). Thus far, two Alphacoronavirus strains, HCoV-229E and HCoV-NL63, along with five Betacoronaviruses, HCoV-HKU1, HCoV-OC43, SARS-CoV, MERS-CoV, and SARS-CoV-2, have been recognized as human coronaviruses (HCoVs). SARS-CoV-2 has resulted in more than six million deaths worldwide since late 2019. The appearance of this novel virus is defined by its high and variable transmission rate (RT) and coexisting asymptomatic and symptomatic propagation within and across animal populations, which has a longer-lasting impact. Most current therapeutic methods aim to reduce the severity of COVID-19 hospitalization and virus symptoms, preventing the infection from progressing from acute to chronic in vulnerable populations. Now, pharmacological interventions including vaccines and others exist, with research ongoing. The only ethical approach to developing herd immunity is to develop and provide vaccines and therapeutics that can potentially improve on the innate and adaptive system responses at the same time. Therefore, several vaccines have been developed to provide acquired immunity to SARS-CoV-2 induced COVID-19-disease. The initial evaluations of the COVID-19 vaccines began in around 2020, followed by clinical trials carried out during the pandemic with ongoing population adverse effect monitoring by respective regulatory agencies. Therefore, durability and immunity provided by current vaccines requires further characterization with more extensive available data, as is presented in this paper. When utilized globally, these vaccines may create an unidentified pattern of antibody responses or memory B and T cell responses that need to be further researched, some of which can now be compared within laboratory and population studies here. Several COVID-19 vaccine immunogens have been presented in clinical trials to assess their safety and efficacy, inducing cellular antibody production through cellular B and T cell interactions that protect against infection. This response is defined by virus-specific antibodies (anti-N or anti-S antibodies), with B and T cell characterization undergoing extensive research. In this article, we review four types of contemporary COVID-19 vaccines, comparing their antibody profiles and cellular aspects involved in coronavirus immunology across several population studies. |
| first_indexed | 2024-03-09T11:05:26Z |
| format | Article |
| id | doaj.art-b5c10b8dec334110a6d3c688ea8ccf05 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T11:05:26Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-b5c10b8dec334110a6d3c688ea8ccf052023-12-01T01:00:45ZengMDPI AGVaccines2076-393X2022-12-011115110.3390/vaccines11010051An Immunological Review of SARS-CoV-2 Infection and Vaccine Serology: Innate and Adaptive Responses to mRNA, Adenovirus, Inactivated and Protein Subunit VaccinesSuhaila A. Al-Sheboul0Brent Brown1Yasemin Shboul2Ingo Fricke3Chinua Imarogbe4Karem H. Alzoubi5Faculty of Applied Medical Sciences, Medical Laboratory Sciences, University of Science and Technology, JordanBiochem123Education, London, UKFaculty of Applied Medical Sciences, Medical Laboratory Sciences, University of Science and Technology, JordanIndependent Researcher, GermanyUKHSA, Rosalind Franklin Laboratory, UKCollege of Pharmacy, University of Sharjah, Sharjah, United Arab EmiratesThe coronavirus disease 2019 (COVID-19) pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, which is defined by its positive-sense single-stranded RNA (ssRNA) structure. It is in the order Nidovirales, suborder Coronaviridae, genus Betacoronavirus, and sub-genus Sarbecovirus (lineage B), together with two bat-derived strains with a 96% genomic homology with other bat coronaviruses (BatCoVand RaTG13). Thus far, two Alphacoronavirus strains, HCoV-229E and HCoV-NL63, along with five Betacoronaviruses, HCoV-HKU1, HCoV-OC43, SARS-CoV, MERS-CoV, and SARS-CoV-2, have been recognized as human coronaviruses (HCoVs). SARS-CoV-2 has resulted in more than six million deaths worldwide since late 2019. The appearance of this novel virus is defined by its high and variable transmission rate (RT) and coexisting asymptomatic and symptomatic propagation within and across animal populations, which has a longer-lasting impact. Most current therapeutic methods aim to reduce the severity of COVID-19 hospitalization and virus symptoms, preventing the infection from progressing from acute to chronic in vulnerable populations. Now, pharmacological interventions including vaccines and others exist, with research ongoing. The only ethical approach to developing herd immunity is to develop and provide vaccines and therapeutics that can potentially improve on the innate and adaptive system responses at the same time. Therefore, several vaccines have been developed to provide acquired immunity to SARS-CoV-2 induced COVID-19-disease. The initial evaluations of the COVID-19 vaccines began in around 2020, followed by clinical trials carried out during the pandemic with ongoing population adverse effect monitoring by respective regulatory agencies. Therefore, durability and immunity provided by current vaccines requires further characterization with more extensive available data, as is presented in this paper. When utilized globally, these vaccines may create an unidentified pattern of antibody responses or memory B and T cell responses that need to be further researched, some of which can now be compared within laboratory and population studies here. Several COVID-19 vaccine immunogens have been presented in clinical trials to assess their safety and efficacy, inducing cellular antibody production through cellular B and T cell interactions that protect against infection. This response is defined by virus-specific antibodies (anti-N or anti-S antibodies), with B and T cell characterization undergoing extensive research. In this article, we review four types of contemporary COVID-19 vaccines, comparing their antibody profiles and cellular aspects involved in coronavirus immunology across several population studies.https://www.mdpi.com/2076-393X/11/1/51COVID-19 vaccinesPfizerBioNTechOxford–AstraZenecaSinopharmNovavax |
| spellingShingle | Suhaila A. Al-Sheboul Brent Brown Yasemin Shboul Ingo Fricke Chinua Imarogbe Karem H. Alzoubi An Immunological Review of SARS-CoV-2 Infection and Vaccine Serology: Innate and Adaptive Responses to mRNA, Adenovirus, Inactivated and Protein Subunit Vaccines Vaccines COVID-19 vaccines Pfizer BioNTech Oxford–AstraZeneca Sinopharm Novavax |
| title | An Immunological Review of SARS-CoV-2 Infection and Vaccine Serology: Innate and Adaptive Responses to mRNA, Adenovirus, Inactivated and Protein Subunit Vaccines |
| title_full | An Immunological Review of SARS-CoV-2 Infection and Vaccine Serology: Innate and Adaptive Responses to mRNA, Adenovirus, Inactivated and Protein Subunit Vaccines |
| title_fullStr | An Immunological Review of SARS-CoV-2 Infection and Vaccine Serology: Innate and Adaptive Responses to mRNA, Adenovirus, Inactivated and Protein Subunit Vaccines |
| title_full_unstemmed | An Immunological Review of SARS-CoV-2 Infection and Vaccine Serology: Innate and Adaptive Responses to mRNA, Adenovirus, Inactivated and Protein Subunit Vaccines |
| title_short | An Immunological Review of SARS-CoV-2 Infection and Vaccine Serology: Innate and Adaptive Responses to mRNA, Adenovirus, Inactivated and Protein Subunit Vaccines |
| title_sort | immunological review of sars cov 2 infection and vaccine serology innate and adaptive responses to mrna adenovirus inactivated and protein subunit vaccines |
| topic | COVID-19 vaccines Pfizer BioNTech Oxford–AstraZeneca Sinopharm Novavax |
| url | https://www.mdpi.com/2076-393X/11/1/51 |
| work_keys_str_mv | AT suhailaaalsheboul animmunologicalreviewofsarscov2infectionandvaccineserologyinnateandadaptiveresponsestomrnaadenovirusinactivatedandproteinsubunitvaccines AT brentbrown animmunologicalreviewofsarscov2infectionandvaccineserologyinnateandadaptiveresponsestomrnaadenovirusinactivatedandproteinsubunitvaccines AT yaseminshboul animmunologicalreviewofsarscov2infectionandvaccineserologyinnateandadaptiveresponsestomrnaadenovirusinactivatedandproteinsubunitvaccines AT ingofricke animmunologicalreviewofsarscov2infectionandvaccineserologyinnateandadaptiveresponsestomrnaadenovirusinactivatedandproteinsubunitvaccines AT chinuaimarogbe animmunologicalreviewofsarscov2infectionandvaccineserologyinnateandadaptiveresponsestomrnaadenovirusinactivatedandproteinsubunitvaccines AT karemhalzoubi animmunologicalreviewofsarscov2infectionandvaccineserologyinnateandadaptiveresponsestomrnaadenovirusinactivatedandproteinsubunitvaccines AT suhailaaalsheboul immunologicalreviewofsarscov2infectionandvaccineserologyinnateandadaptiveresponsestomrnaadenovirusinactivatedandproteinsubunitvaccines AT brentbrown immunologicalreviewofsarscov2infectionandvaccineserologyinnateandadaptiveresponsestomrnaadenovirusinactivatedandproteinsubunitvaccines AT yaseminshboul immunologicalreviewofsarscov2infectionandvaccineserologyinnateandadaptiveresponsestomrnaadenovirusinactivatedandproteinsubunitvaccines AT ingofricke immunologicalreviewofsarscov2infectionandvaccineserologyinnateandadaptiveresponsestomrnaadenovirusinactivatedandproteinsubunitvaccines AT chinuaimarogbe immunologicalreviewofsarscov2infectionandvaccineserologyinnateandadaptiveresponsestomrnaadenovirusinactivatedandproteinsubunitvaccines AT karemhalzoubi immunologicalreviewofsarscov2infectionandvaccineserologyinnateandadaptiveresponsestomrnaadenovirusinactivatedandproteinsubunitvaccines |